意大利血液系统恶性肿瘤患者COVID-19严重程度的临床特征与危险因素:一项回顾性、多中心、队列研究
该多中心回顾性队列研究纳入2020年2月25日至5月18日意大利66家医院收治的536例成人血液系统恶性肿瘤合并实验室确诊且有症状的COVID-19患者,中位随访20天,198例(37%)死亡。标准化死亡比相较于意大利COVID-19普通人群为2.04(95% CI 1.77-2.34),相较于无COVID-19的血液系统恶性肿瘤队列为41.3(95% CI 38.1-44.9)。高龄、疾病进展状态、急性髓系白血病、惰性非霍奇金淋巴瘤、侵袭性非霍奇金淋巴瘤、浆细胞肿瘤及重症或危重症COVID-19与更差的总生存相关。
要点
- 血液系统恶性肿瘤合并COVID-19住院患者死亡率高,198/536例(37%)死亡。
- 标准化死亡比相较于意大利COVID-19普通人群为2.04(95% CI 1.77-2.34)。
- 高龄、疾病进展、急性髓系白血病、淋巴瘤、浆细胞肿瘤及重症COVID-19与更差总生存相关。
核心结论
- 血液系统恶性肿瘤患者合并COVID-19的结局劣于意大利COVID-19普通人群及无COVID-19的血液系统恶性肿瘤患者。
- 血液系统恶性肿瘤合并COVID-19住院患者死亡率高,凸显至少在有有效疫苗或治疗策略之前采取积极感染预防策略的必要性。
研究设计与样本
- 多中心、回顾性、队列研究,纳入2020年2月25日至5月18日意大利66家医院收治的年龄≥18岁、WHO定义的血液系统恶性肿瘤合并实验室确诊且有症状的COVID-19成人患者,共536例。
- 数据截止日期为2020年6月22日,中位随访20天(IQR 10-34)。
- 计算研究队列观察死亡与基于意大利COVID-19人群及意大利31 993例无COVID-19血液系统恶性肿瘤队列(数据截至2019年3月1日)分层死亡率所得预期死亡之间的标准化死亡比。
- 采用多变量Cox比例风险模型识别与总生存相关的因素。
- 研究注册于ClinicalTrials.gov,NCT04352556,研究的前瞻性部分正在进行中。
主要发现
- 536例患者中198例(37%)死亡;451例住院患者中440例(98%)完成住院病程(活体出院或死亡);85例(16%)按门诊管理。
- 与意大利COVID-19普通人群相比,全研究队列标准化死亡比为2.04(95% CI 1.77-2.34),年龄<70岁者为3.72(95% CI 2.86-4.64)。
- 与无COVID-19的血液系统恶性肿瘤队列相比,标准化死亡比为41.3(95% CI 38.1-44.9)。
- 与更差总生存相关的因素包括:高龄(HR 1.03,95% CI 1.01-1.05)、疾病进展状态(HR 2.10,95% CI 1.41-3.12)、急性髓系白血病(HR 3.49,95% CI 1.56-7.81)、惰性非霍奇金淋巴瘤(HR 2.19,95% CI 1.07-4.48)、侵袭性非霍奇金淋巴瘤(HR 2.56,95% CI 1.34-4.89)、浆细胞肿瘤(HR 2.48,95% CI 1.31-4.69)及重症或危重症COVID-19(HR 4.08,95% CI 2.73-6.09)。
临床怎么用
- 原文结论指出,血液系统恶性肿瘤合并COVID-19住院患者死亡率高,凸显至少在有有效疫苗或治疗策略之前采取积极感染预防策略的必要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19. METHODS: This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a WHO-defined haematological malignancy admitted to 66 Italian hospitals between Feb 25 and May 18, 2020, with laboratory-confirmed and symptomatic COVID-19. Data cutoff for this analysis was June 22, 2020. The primary outcome was mortality and evaluation of potential predictive parameters of mortality. We calculated standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates of the Italian population with COVID-19 and an Italian cohort of 31 993 patients with haematological malignancies without COVID-19 (data up to March 1, 2019). Multivariable Cox proportional hazards model was used to identify factors associated with overall survival. This study is registered with ClinicalTrials.gov, NCT04352556, and the prospective part of the study is ongoing. FINDINGS: We enrolled 536 patients with a median follow-up of 20 days (IQR 10-34) at data cutoff, 85 (16%) of whom were managed as outpatients. 440 (98%) of 451 hospitalised patients completed their hospital course (were either discharged alive or died). 198 (37%) of 536 patients died. When compared with the general Italian population with COVID-19, the standardised mortality ratio was 2·04 (95% CI 1·77-2·34) in our whole study cohort and 3·72 (2·86-4·64) in individuals younger than 70 years. When compared with the non-COVID-19 cohort with haematological malignancies, the standardised mortality ratio was 41·3 (38·1-44·9). Older age (hazard ratio 1·03, 95% CI 1·01-1·05); progressive disease status (2·10, 1·41-3·12); diagnosis of acute myeloid leukaemia (3·49, 1·56-7·81), indolent non-Hodgin lymphoma (2·19, 1·07-4·48), aggressive non-Hodgkin lymphoma (2·56, 1·34-4·89), or plasma cell neoplasms (2·48, 1·31-4·69), and severe or critical COVID-19 (4·08, 2·73-6·09) were associated with worse overall survival. INTERPRETATION: This study adds to the evidence that patients with haematological malignancies have worse outcomes than both the general population with COVID-19 and patients with haematological malignancies without COVID-19. The high mortality among patients with haematological malignancies hospitalised with COVID-19 highlights the need for aggressive infection prevention strategies, at least until effective vaccination or treatment strategies are available. FUNDING: Associazione italiana contro le leucemie, linfomi e mieloma-Varese Onlus.
引用
- Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020. PMID: 32798473. doi:10.1016/S2352-3026(20)30251-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。